Amicus Therapeutics Inc (FRA:AM6)
€ 9.3 0.2 (2.2%) Market Cap: 2.82 Bil Enterprise Value: 3.01 Bil PE Ratio: 0 PB Ratio: 16.43 GF Score: 78/100

Amicus Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 10, 2021 / 07:30PM GMT
Release Date Price: €9.7 (+2.11%)
Michael Eric Ulz;Bradley L. Campbell<
Morgan Stanley, Research Division - Equity Analyst

All right. Great. Good afternoon, and thanks for joining us at the Morgan Stanley Healthcare Conference. I'm Mike Ulz, one of the biotech analysts here. It's my pleasure to introduce Brad Campbell, President and Chief Operating Officer; as well as Jeff Castelli, Chief Development Officer from Amicus Therapeutics.

Just as a quick reminder, the format for today is a fireside chat. So please feel free to ask a question if you have any, and you can do so through the portal, and we'll be sure to address it during our discussion. Before we get started, I just need to read a quick disclaimer. So for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative.

And with that, I will turn it over to Brad to make a few introductory comments. Brad?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot